Literature DB >> 11141490

beta-site APP cleaving enzyme mRNA expression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging.

M C Irizarry1, J J Locascio, B T Hyman.   

Abstract

The principal enzyme responsible for the beta-site cleavage of amyloid precursor protein (APP) in the brain is a membrane-bound aspartyl protease beta-site APP cleaving enzyme (BACE). We examined human APP (hAPP) and BACE mRNA expression by in situ hybridization in young and old hAPP transgenic mice from two lines: Tg2576, hAPP KM670-671NL (hAPP(Sw)) at 4 and 15 months; and PDAPP, hAPP V717F, at 4 and 11 months. In transgene-positive mice from both lines, hAPP expression was most prominent in cortical, cerebellar, and hippocampal neuronal populations. Cingulate, entorhinal, and hippocampal amyloid burden in transgene-positive 16-month Tg2576 mice was 4 to 8%, and in 12-month PDAPP mice, 2 to 4%; there was no cerebellar amyloid deposition. BACE expression in transgenic and nontransgenic mice was highest in the cerebellar granule cell layer and hippocampal neuronal layers, intermediate in cortex, lower in subcortical regions, and minimal or absent in white matter of the cerebellum. Emulsion-dipped sections confirmed a predominantly neuronal pattern of expression. The amount of hybridization signal did not differ between transgenic and nontransgenic mice, or young and old mice, within each line. Thus, hAPP and endogenous BACE expression in similar anatomical localizations allow for processing of hAPP and Abeta formation in hAPP transgenic mice, but these are modified by additional age-related and anatomical factors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11141490      PMCID: PMC1850271          DOI: 10.1016/s0002-9440(10)63955-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.

Authors:  R Yan; M J Bienkowski; M E Shuck; H Miao; M C Tory; A M Pauley; J R Brashier; N C Stratman; W R Mathews; A E Buhl; D B Carter; A G Tomasselli; L A Parodi; R L Heinrikson; M E Gurney
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

2.  Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.

Authors:  K Johnson-Wood; M Lee; R Motter; K Hu; G Gordon; R Barbour; K Khan; M Gordon; H Tan; D Games; I Lieberburg; D Schenk; P Seubert; L McConlogue
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

3.  Expression analysis of BACE2 in brain and peripheral tissues.

Authors:  B D Bennett; S Babu-Khan; R Loeloff; J C Louis; E Curran; M Citron; R Vassar
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

4.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology.

Authors:  C Sturchler-Pierrat; D Abramowski; M Duke; K H Wiederhold; C Mistl; S Rothacher; B Ledermann; K Bürki; P Frey; P A Paganetti; C Waridel; M E Calhoun; M Jucker; A Probst; M Staufenbiel; B Sommer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

5.  Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP(V717F) transgenic mice.

Authors:  M C Irizarry; B S Cheung; G W Rebeck; S M Paul; K R Bales; B T Hyman
Journal:  Acta Neuropathol       Date:  2000-11       Impact factor: 17.088

6.  Developmental regulation of presenilin mRNA expression parallels notch expression.

Authors:  O Berezovska; M Q Xia; K Page; W Wasco; R E Tanzi; B T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  1997-01       Impact factor: 3.685

7.  In situ hybridization analysis of presenilin 1 mRNA in Alzheimer disease and in lesioned rat brain.

Authors:  K Page; R Hollister; R E Tanzi; B T Hyman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

8.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

9.  Differential regional and cellular distribution of beta-amyloid precursor protein messenger RNAs containing and lacking the Kunitz protease inhibitor domain in the brain of human, rat and mouse.

Authors:  C Solà; G Mengod; A Probst; J M Palacios
Journal:  Neuroscience       Date:  1993-03       Impact factor: 3.590

10.  Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease.

Authors:  E Masliah; A Sisk; M Mallory; L Mucke; D Schenk; D Games
Journal:  J Neurosci       Date:  1996-09-15       Impact factor: 6.167

View more
  21 in total

1.  Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients.

Authors:  Rena Li; Kristina Lindholm; Li-Bang Yang; Xu Yue; Martin Citron; Riqiang Yan; Thomas Beach; Lucia Sue; Marwan Sabbagh; Huaibin Cai; Philip Wong; Donald Price; Yong Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

2.  Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain.

Authors:  T M Wengenack; D A Reyes; G L Curran; B J Borowski; J Lin; G M Preboske; S S Holasek; E J Gilles; R Chamberlain; M Marjanska; C R Jack; M Garwood; J F Poduslo
Journal:  Neuroimage       Date:  2010-08-20       Impact factor: 6.556

3.  BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: differential Aβ antibody labeling of early-onset axon terminal pathology.

Authors:  Yan Cai; Xue-Mei Zhang; Lauren N Macklin; Huaibin Cai; Xue-Gang Luo; Salvatore Oddo; Frank M Laferla; Robert G Struble; Gregory M Rose; Peter R Patrylo; Xiao-Xin Yan
Journal:  Neurotox Res       Date:  2011-07-02       Impact factor: 3.911

4.  CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition.

Authors:  Justyna A Dobrowolska; Maria S Michener; Guoxin Wu; Bruce W Patterson; Robert Chott; Vitaliy Ovod; Yuriy Pyatkivskyy; Kristin R Wildsmith; Tom Kasten; Parker Mathers; Mandy Dancho; Christina Lennox; Brad E Smith; David Gilberto; Debra McLoughlin; Daniel J Holder; Andrew W Stamford; Kevin E Yarasheski; Matthew E Kennedy; Mary J Savage; Randall J Bateman
Journal:  J Neurosci       Date:  2014-06-11       Impact factor: 6.167

Review 5.  Filling the void: a role for exercise-induced BDNF and brain amyloid precursor protein processing.

Authors:  Rebecca E K MacPherson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-08-16       Impact factor: 3.619

6.  Reduction of β-amyloid and γ-secretase by calorie restriction in female Tg2576 mice.

Authors:  Marissa J Schafer; Melissa J Alldred; Sang Han Lee; Michael E Calhoun; Eva Petkova; Paul M Mathews; Stephen D Ginsberg
Journal:  Neurobiol Aging       Date:  2014-12-04       Impact factor: 4.673

7.  BACE1 and BACE2 enzymatic activities in Alzheimer's disease.

Authors:  Rachel R Ahmed; Christopher J Holler; Robin L Webb; Feng Li; Tina L Beckett; M Paul Murphy
Journal:  J Neurochem       Date:  2009-12-04       Impact factor: 5.372

8.  Asynchronous evolutionary origins of Aβ and BACE1.

Authors:  D Blaine Moore; Madelyn A Gillentine; Nathalie M Botezatu; Kyle A Wilson; Ashley E Benson; James A Langeland
Journal:  Mol Biol Evol       Date:  2013-12-19       Impact factor: 16.240

9.  Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice.

Authors:  Matthew J Chiocco; Laura Shapiro Kulnane; Linda Younkin; Steve Younkin; Geneviève Evin; Bruce T Lamb
Journal:  J Biol Chem       Date:  2004-09-27       Impact factor: 5.157

10.  The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.

Authors:  S L Cole; R Vassar
Journal:  Curr Genomics       Date:  2007-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.